CAPR - Capricor Therapeutics updates on COVID-19 vaccine pre-clinical study

Capricor Therapeutics (CAPR) announces new advances from its positive preclinical study for a multivalent exosome-based mRNA vaccine for COVID-19 have been posted and has been submitted for publication.Data showed that exosome-mRNA formulations can drive functional enzyme expression in vivo, opening the opportunity for therapeutic exosome-mRNA formulations.Superior expression from exosome-mRNA formulations compared to Lipid Nanoparticle ((LNP))-mRNA formulationsThe data showed that functional RNA expression in vivo further showing the power of our exosome platform to potentially expand into areas beyond SARS-CoV-2.The company said it is planning to meet with the U.S. FDA this quarter to discuss next steps for a clinical development strategy for its exosome-mRNA vaccine.

For further details see:

Capricor Therapeutics updates on COVID-19 vaccine pre-clinical study